Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)

Launched by INSTITUT DU CANCER DE MONTPELLIER - VAL D'AURELLE · Mar 13, 2019

Keywords

ClinConnect Summary

The MESOTIP trial is studying a new treatment approach for patients with a type of cancer called malignant peritoneal mesothelioma. This trial compares two treatment methods: one group of patients will receive a combination of a special type of chemotherapy given directly into the abdomen (called PIPAC) along with standard chemotherapy, while another group will receive only the standard chemotherapy. The goal is to see if the combination treatment helps patients live longer and have better outcomes.

To participate in this trial, patients must be at least 18 years old and have a confirmed diagnosis of malignant peritoneal mesothelioma without having received any previous treatments for this condition. Other important factors include not having serious health issues that would prevent them from undergoing the treatments, and they should be able to provide consent to participate. If eligible, patients can expect to receive the study treatment, regular check-ups, and support throughout the trial. It's a promising opportunity for those looking for new options in their fight against this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years
• • 2. PS (or WHO) \<2
• • 3. Histologically-confirmed diagnosis of peritoneal malignant mesothelioma
• • 4. No previous line of treatment (both medical and surgical oncologic treatments) for this disease
• • 5. Peritoneal Carcinomatosis Index (PCI)\>27 or at least 4 on the small bowel with serosal involvement contraindicating the cytoreductive surgery because of the impossibility to preserve a length \>=1.5 m of uninvolved small bowel
• • 6. Written and dated informed consent
• • 7. Affiliated to the French national social security system
• Exclusion Criteria:
• • 1. WHO performance status ≥ 2
• • 2. Any contraindication to chemotherapy and/or radiotherapy
• • 3. Any contraindication to repeated laparoscopy
• • 4. Symptomatic cardiac or coronary insufficiency
• • 5. Severe renal insufficiency
• • 6. Progressive active infection or any other severe medical condition
• • 7. Intestinal occlusion non responsive to medical treatment
• • 8. Other cancer treated within the last 2 years except in situ cervical carcinoma or basocellular/spinocellular carcinoma
• • 9. Pregnant or breast-feeding woman
• • 10. Previously operated patients where laparoscopy is not feasible
• • 11. Persons deprived of liberty or under guardianship or incapable of giving consent
• • 12. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule